Kaye Scholer advised longtime client Pfizer Inc. in its agreement to acquire InnoPharma, Inc., a privately held pharmaceutical development company. Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.
The Kaye Scholer Corporate team was led by Partner Lowell Dashefsky, Counsel Aaron Gardner and Associate Viktoriya Karshenboyem, with support from Partners Laurie Abramowitz (Tax), Jeffrey London (Executive Compensation & Employee Benefits), David Barr (Intellectual Property) and Andres Liivak (Life Sciences); Counsels Kathleen Wechter (Executive Compensation & Employee Benefits)and Irv Hepner (Real Estate); and Associates Brian Witkowski (Executive Compensation & Employee Benefits), Amanda Myers (Real Estate) and Connie Ericson (Environmental).
